98 related articles for article (PubMed ID: 8297104)
41. Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 prostate carcinoma cells.
Qiao L; Pizzolo JG; Melamed MR
Biochem Biophys Res Commun; 1994 Jun; 201(2):581-8. PubMed ID: 7911660
[TBL] [Abstract][Full Text] [Related]
42. Small cell lung cancer and topoisomerases.
Giaccone G
Anticancer Res; 1994; 14(1B):269-76. PubMed ID: 8166466
[TBL] [Abstract][Full Text] [Related]
43. Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity.
Chikamori K; Grabowski DR; Kinter M; Willard BB; Yadav S; Aebersold RH; Bukowski RM; Hickson ID; Andersen AH; Ganapathi R; Ganapathi MK
J Biol Chem; 2003 Apr; 278(15):12696-702. PubMed ID: 12569090
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of fibroblast hyaluronic acid production by suramin.
August EM; Duncan KL; Malinowski NM; Cysyk RL
Oncol Res; 1993; 5(10-11):415-22. PubMed ID: 8054702
[TBL] [Abstract][Full Text] [Related]
45. Accessibility to DNA in carcinoma chromatin is promoted by nanomolar okadaic acid: effect on AT-rich DNA binding proteins.
Rieber MS; Rieber M
Cancer Res; 1992 Nov; 52(22):6397-9. PubMed ID: 1330292
[TBL] [Abstract][Full Text] [Related]
46. Casein kinase II-dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast.
Nakazawa N; Arakawa O; Ebe M; Yanagida M
J Biol Chem; 2019 Mar; 294(10):3772-3782. PubMed ID: 30635402
[TBL] [Abstract][Full Text] [Related]
47. Mechanisms of growth stimulation by suramin in non-small-cell lung cancer cell lines.
Lokshin A; Peng X; Campbell PG; Barsouk A; Levitt ML
Cancer Chemother Pharmacol; 1999; 43(4):341-7. PubMed ID: 10071987
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of DNA topoisomerases II and/or I by pyrazolo[1,5-a]indole derivatives and their growth inhibitory activities.
Umemura K; Mizushima T; Katayama H; Kiryu Y; Yamori T; Andoh T
Mol Pharmacol; 2002 Oct; 62(4):873-80. PubMed ID: 12237334
[TBL] [Abstract][Full Text] [Related]
49. Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
Maulik G; Bharti A; Khan E; Broderick RJ; Kijima T; Salgia R
J Environ Pathol Toxicol Oncol; 2004; 23(4):237-51. PubMed ID: 15511212
[TBL] [Abstract][Full Text] [Related]
50. Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates.
Meikle I; Cummings J; Macpherson JS; Hadfield JA; Smyth JF
Biochem Pharmacol; 1995 Jun; 49(12):1747-57. PubMed ID: 7598737
[TBL] [Abstract][Full Text] [Related]
51. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells.
Bojanowski K; Lelievre S; Markovits J; Couprie J; Jacquemin-Sablon A; Larsen AK
Proc Natl Acad Sci U S A; 1992 Apr; 89(7):3025-9. PubMed ID: 1313577
[TBL] [Abstract][Full Text] [Related]
52. Phosphorylation-independent stimulation of DNA topoisomerase II alpha activity.
Kimura K; Saijo M; Tanaka M; Enomoto T
J Biol Chem; 1996 May; 271(18):10990-5. PubMed ID: 8631919
[TBL] [Abstract][Full Text] [Related]
53. Topoisomerase expression in cancer cell lines and clinical samples.
Doyle LA
Cancer Chemother Pharmacol; 1994; 34 Suppl():S32-40. PubMed ID: 8070025
[TBL] [Abstract][Full Text] [Related]
54. Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site.
Grozav AG; Willard BB; Kozuki T; Chikamori K; Micluta MA; Petrescu AJ; Kinter M; Ganapathi R; Ganapathi MK
Proteomics; 2011 Mar; 11(5):829-42. PubMed ID: 21280220
[TBL] [Abstract][Full Text] [Related]
55. Effects of suramin on human lung cancer cell lines.
Rubio GJ; Pinedo HM; Virizuela J; van Ark-Otte J; Giaccone G
Eur J Cancer; 1995; 31A(2):244-51. PubMed ID: 7718332
[TBL] [Abstract][Full Text] [Related]
56. Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes.
Coutts J; Plumb JA; Brown R; Keith WN
Br J Cancer; 1993 Oct; 68(4):793-800. PubMed ID: 8398710
[TBL] [Abstract][Full Text] [Related]
57. Identification of the nature of modification that causes the shift of DNA topoisomerase II beta to apparent higher molecular weight forms in the M phase.
Kimura K; Nozaki N; Saijo M; Kikuchi A; Ui M; Enomoto T
J Biol Chem; 1994 Oct; 269(40):24523-6. PubMed ID: 7929118
[TBL] [Abstract][Full Text] [Related]
58. [Inhibitory effect of galangin on DNA topoisomerases in lung cancer cells].
Zhao X; Zhang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 May; 40(5):479-85. PubMed ID: 26032076
[TBL] [Abstract][Full Text] [Related]
59. Amplification of the topoisomerase II alpha gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II alpha and beta loci in normal tissue.
Keith WN; Tan KB; Brown R
Genes Chromosomes Cancer; 1992 Mar; 4(2):169-75. PubMed ID: 1373318
[TBL] [Abstract][Full Text] [Related]
60. Regulation of human natural killer-cell lytic activity by serine/threonine phosphatases and kinases.
Bajpai A; Brahmi Z
Ann N Y Acad Sci; 1995 Sep; 766():216-9. PubMed ID: 7486662
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
